The Pharmaceutical Industry and Global HealthcarePresented By –Anil Sharma
KEY FACTSResearch & development ➜ It takes 10-15 years to develop a medicine or vaccine. ➜ The research-based pharmaceutical industry currently spends over USD 100 billion (EUR 75 billion) on R&D. ➜ In 2010, there were 878 medicines in the pipeline for all types of cancer, 193 for diabetes and 303 for rare diseases. ➜ In 2009, 25 new pharmaceuticals were launched, out of more than 3,050 compounds in development. ➜ In 2006-2010, the number of new chemical or biological entities launched on the world market fell to 151 from 211 a decade earlier. ➜ It costs an average of USD 1.38 billion to develop a single medicine. ➜ In 2010, five of the 10 leading global R&D firms were pharmaceutical companies.
The research-based pharmaceuticalindustry’s contribution to a healthy society➜ In 2010, the number of medicines in development for particular disease areas were:– Cancer: 878– Cardiovascular disorders: 237– Diabetes mellitus: 193– HIV/AIDS: 81– Rare diseases: 303➜ For every USD 24 spent on new medicines for cardiovasculardiseases in OECD countries, USD 89 were saved in hospitalizationand other healthcare costs.
The pharmaceutical market ➜ The pharmaceutical market will reach nearly USD 1,100 billion by 2015. ➜ Leading emerging countries will account for 28 % of global spending on pharmaceuticals by 2015, compared to 12 % in 2005. ➜ The US share will decline from 41 % in 2005 to 31 % in 2015, while Europe’s share will fall from 27 % in 2005 to 19 % in 2015.• This growth is coming mainly from market expansion in the leading emerging countries and from generics. In developed markets, sales of new branded medicines are expected to increase by USD 119 billion to 2015, but this will be offset by losses due to patent expiration of USD 120 billion. On the other hand, generic sales in developed markets are expected to grow by USD 47 billion. The US share of global spending will decline from 41 % in 2005 to 31 % in 2015, while the European share of spending will decline from 27 % to 19 %. Meanwhile, the leading emerging countries will account for 28 % of global spending in 2015 from 12 % in 2005.
Generic versus branded pharmaceutical products• Branded products accounted for nearly two thirds of global pharmaceutical spending in 2010. However, as patents expire in developed markets, that share is expected to decline. Spending on generic medicines is driving most of the growth in the leading emerging markets, which will contribute to the increase in the share of generic spending. The revenues from generics in 2015 are expected to reach USD 400-430 billion, 70 % of which will be outside developed markets.
Pharma By 2020 – Sales and Marketing● By 2020 the current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model as the industry shifts from a mass-market to a target-market approach to increase revenue.● Companies will need to demonstrate that their brand adds value to patients and they will have to offer a package of products and health services that the market not only wants and needs but is willing to pay a premium for.● The industry faces that are reshaping the pharmaceutical marketplace.• Chronic disease is soaring• Healthcare policy makers and payers are increasingly mandating what doctors can prescribe• Pay-for-performance is on the rise• The boundaries between different forms of healthcare are blurring• The markets of the developing world, where demand for medicines is likely to grow most rapidly over the next 13 years, are highly varied• Governments are beginning to focus on prevention rather than treatment• Regulators are becoming more risk-averse.
Indian Pharma, healthcare and Life Sciences Industry Future• According to a new Research and Market’s report, “Indian Pharma Sector Forecast 2014.” India will emerge as a leading global player in pharmaceutical industry by 2020, securing a place among the top five major global markets, according to Ikon Marketing Consultant (IMC). Also, Associated Chambers of Commerce and Industry (Assocham) has said it expects the Indian pharmaceutical industry to reach US$ 20 billion by 2015, making it one of the worlds top 10 pharmaceuticals markets.• India has a strong local manufacturing base and domestic players are developing substantial international presence. Healthcare is also one of the largest service sector industries in India, in terms of revenue and employment. Rising health awareness and increasing government expenditure on healthcare sector is driving growth in the sector. Medical tourism and health insurance are also on a rise, with significant growth in healthcare sector and establishment of large number of hospitals, both public and private. The Indian healthcare industry, estimated at US$ 50 billion, is expected to reach over US$ 75 billion by 2012, and US$ 100 billion by 2015.
A LOO K IN TO THE Pharmaceutical industry R&D pipeline• Of all the different industrial sectors, the research-based pharmaceutical industry has consistently invested the most in R&D, even in times of economic turmoil and financial crisis. Compared with other high-technology industries, the annual R&D spending of USD 120 billion by the pharmaceutical industry is five times greater than the R&D investments of the aerospace and defense industries, 3.75 times more than the chemicals industry, and 2.5 times more than the software and computer services industry In the United States, R&D investments of pharmaceutical companies have grown consistently over the past 15 years, and have more than doubled the publicly-funded National Institutes of Health’s (NIH) expenditures in 2009.• Furthermore, the research-based pharmaceutical industry in Japan spends every fifth Yen it earns from sales on R&D, in the United States every sixth Dollar and in the European Union every seventh Euro. No other business sector has such high levels of R&D intensity.According to the EU Industrial R&D Scoreboard 2010, which looked at the EU, the US and Japan, the pharmaceutical industry was the top R&D investor in 2009, with positive spending growth, whereas in most of the other sectors, with the exception of health care equipment and services, spending declined.
Pharmaceutical R&D and its impact on Global health• Pharmaceutical R&D has dramatically improved the lives of patients. Medical discoveries big and small have increased life expectancy and resulted in a better quality of life for many. Vaccines have enabled the global eradication of smallpox and the regional elimination of polio and measles. Currently, vaccines save the lives of over 2 million children each year.• Between 2000 and 2006, immunization campaigns cut the number of deaths caused by measles by 68 %, with a reduction of 91 % in Africa. Since 1928, scientists have discovered and developed 19 classes of antibiotics, leading to the treatment and cure of several thousand types of infection and saving over 200 million lives.• With the help of major medical discoveries, the research-based pharmaceutical industry has developed more than 20 antiretroviral treatments for HIV/AIDS, essential in control of the epidemic. In 2010, there were 48 medicines in the pipeline for malaria, 81 medicines in development for HIV/AIDS, 878 for all types of cancer, 193 for diabetes and 303 for rare diseases. It is estimated that medicines prevent at least 3 million deaths from malaria and save 750,000 children from disability every year.• Pharmaceutical progress has led to a dramatic decline in death rates for diseases such as HIV/AIDS, cancer, polio and measles. For example, death Today, if a patient is diagnosed with leukaemia early enough, he or she will be able to drive the cancer into remission by taking a single pill each day. High cholesterol and other cardiovascular diseases, which required extensive treatment in the 1970s, can now be easily managed by taking pills. Meanwhile, improvements in existing cancer treatments have cut annual death rates in half.
20 largest pharmaceuiical and biotech companies• Pfizer $57,747• Novartis $47,935• Sanofi $42,779• Merck $41,289• GlaxoSmithKline $35,594• AstraZeneca $32,981• Johnson & Johnson $24,368• Eli Lilly & Co. $22,608• Abbott Laboratories $22,435• Bristol-Myers Squibb $21,244• Takeda Pharma $17,257• Teva $16,689• Boehringer-Ingelheim $14,058• Bayer Schering $13,853• Astellas $12,311• Daiichi-Sankyo $11,338• Otsuka Pharmaceutical $9,935• Gilead Sciences $8,102• EISAI $7,710• Mylan $6,106Note: In all Top Company profiles, dollar amounts are in millions.
List of Top 10 Pharmaceutical Companies in India -Ranbaxy -Dr. Reddys Laboratories -Cipla -Sun Pharma Industries -Lupin Labs -Aurobindo Pharma -Glaxo SmithKine Pharma -Cadila Healthcare -Aventis Pharma -Ipca LaboratoriesIndian Pharma sector is performing well and contributing good to Indian GDP. Even at the time of recession also, this sector has not effected.
Top Eight Health Care Companies in India• IndoGlobal Health Sciences Private Limited• Cadilla Healthcare• Whole Health Now• Advanced Healthcare Resources of India• Cipla• Nicholas Piramal India Private Limited• Serum Institute of India Limited• Sun Health Care
7 Top Medical Device Companies To Consider Working For - 2012
Some Other leaders In Pharma/Healthcare and Life Sciences- Research Market• Thermo fisher Philips• Waters Zimmer• Shimadzu Scientific Synthes• PerkinElmer Smith&Nephew• Bio-Rad Laboratories SJM• Life Technologies Sun Pharma• Spinco Biotech Cipla• Merk Milipore Ranbaxy• RFCL Dr. reddy• Karl Storz Glenmark• Olympus Lupin• Bbruan Medical Fresenious Kabi• Baxter Fresenious Medical Care• Aesculap Novartis• Siemense healthcare Astra Zeneca• GE Healthcare Pfizer• Sanofi Aventis Abbott
Conclusion• Pharmaceutical innovations are behind some of the greatest achievements in modern medicine. We live longer and healthier lives than previous generations.• Medical advances allow people to enjoy a better quality of life and increase their productivity, contributing to the overall prosperity of society.• Pharmaceutical innovation also creates jobs, spurs technology and represents an important source of income. Unfortunately, not everyone has yet fully benefited from these medical advances.• Poverty and great wealth inequality between and within countries mean that many do not have access even to the simplest healthcare interventions. Addressing these issues is a complex challenge that requires long-term commitment from governments, civil society and the private sector. Through differential pricing schemes, donation programs and technology transfer initiatives, the pharmaceutical industry has been doing its part to help those in greatest need to also enjoy the benefits of medical progress. Much still needs to be done; the path forward will require a constant rethinking on how to maximize the research-based industry’s positive impact on the health and prosperity of societies.